Aurobindo Pharma Subsidiary Acquires Khandelwal Labs' Non-Oncology Portfolio for ₹325 Crore
核心洞察
Auro Pharma (搜索), a subsidiary of Aurobindo Pharma, has acquired the non-oncology prescription formulations business of Khandelwal Laboratories (搜索) for ₹325 crore on a slump sale basis.
The acquisition includes 23 brands across 67 SKUs and 9 pipeline products, with anti-infectives (搜索) and pain management (搜索) representing the major therapeutic portfolios.
The acquired business generated ₹113.5 crore in revenue during 2024-25 with an EBITDA of ₹28.9 crore and includes a 470-strong field force and over 1,600 stockists.
Auro Pharma (搜索) Ltd, a subsidiary of Aurobindo Pharma, has acquired the branded non-oncology prescription formulations business of Mumbai-based Khandelwal Laboratories (搜索) Private Ltd for ₹325 crore. The transaction, structured as a slump sale on a going concern basis, represents a strategic expansion of Aurobindo's domestic pharmaceutical portfolio.
Acquisition Details and Portfolio Composition
The acquired business encompasses 23 brands marketed across 67 stock keeping units (SKUs) along with 9 pipeline products currently under development. Anti-infectives (搜索) and pain management (搜索) constitute the major therapeutic portfolios within this acquisition, areas that align with Aurobindo's existing capabilities and market focus.
The cash consideration of ₹325 crore is subject to true-up adjustments for working capital as outlined in the definitive agreements. Notably, the acquisition involves only the specific business assets and does not include any control or shares of Khandelwal Laboratories (搜索) itself.
Financial Performance and Infrastructure
The non-oncology business demonstrated solid financial performance in 2024-25, generating a turnover of ₹113.53 crore with an EBITDA of ₹28.9 crore. This represents an EBITDA margin of approximately 25.5%, indicating the profitability of the acquired operations.
The acquisition includes substantial commercial infrastructure, featuring a field force of around 470 employees and an established distribution network comprising more than 1,600 stockists and related distribution infrastructure. This existing network provides immediate market access and operational capabilities for the acquired brands.
Strategic Rationale and Market Impact
According to Aurobindo Pharma's filing with the BSE, the acquisition will complement the company's existing product portfolios and facilitate expansion in the domestic pharmaceutical market. The addition of established brands in pain management (搜索) and anti-infectives (搜索) strengthens Aurobindo's presence in these therapeutic segments.
The transaction is scheduled to become effective on January 1, 2026, providing time for integration planning and regulatory approvals. This timeline suggests a structured approach to incorporating the acquired assets into Aurobindo's existing operations while maintaining business continuity for the transferred brands and their market presence.